Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers.
Journal: Future oncology (London, England)
Published: November 24, 2025
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.
Journal: Cancer research communications
Published: August 18, 2021
Curative-Intent Treatment with Durvalumab in Early-Stage Cancers.
Journal: Advances in therapy
Published: January 22, 2021
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Journal: Journal of translational medicine
Published: November 19, 2019
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Journal: JAMA oncology
Published: November 02, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Journal: The New England journal of medicine
Published: October 04, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 30, 2018
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: September 09, 2017
NADPH oxidase 1 supports proliferation of colon cancer cells by modulating reactive oxygen species-dependent signal transduction.
Journal: The Journal of biological chemistry
Published: November 22, 2016
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Journal: Cancer chemotherapy and pharmacology
Published: May 14, 2014
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: October 25, 2013
Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors.
Journal: Investigational new drugs
Published: October 16, 2013
Last Updated: 09/26/2026